Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vardenafil vs Sildenafil for PPHN
NCT06860399Phase 2Completed
- Sponsor
- Damascus University
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vardenafil in persistent pulmonary hypertension of the newborn (PPHN) (2 arms), sponsored by Damascus University. Primary endpoints: Time to Normalization of Pulmonary Hypertension and Time to Normalization of Pulmonary Resistance. Started May 2023; status: completed.
02
Drugs
vardenafil
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on NCT06860399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860399.